Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Lisa A Moreau"'
Autor:
Rani E George, Edward F Attiyeh, Shuli Li, Lisa A Moreau, Donna Neuberg, Cheng Li, Edward A Fox, Matthew Meyerson, Lisa Diller, Paolo Fortina, A Thomas Look, John M Maris
Publikováno v:
PLoS ONE, Vol 2, Iss 2, p e255 (2007)
Neuroblastomas are characterized by chromosomal alterations with biological and clinical significance. We analyzed paired blood and primary tumor samples from 22 children with high-risk neuroblastoma for loss of heterozygosity (LOH) and DNA copy numb
Externí odkaz:
https://doaj.org/article/5a8b57bc42164cfa9f7e9f15eb369f48
Autor:
Roger A. Greenberg, Jukka S. Moilanen, Lisa A. Moreau, Kym M. Boycott, A. Micheil Innes, David A. Dyment, Jacek Majewski, Martin Kircher, Jeremy Schwartzentruber, Marketta Kähkönen, Lei Tian, Sarah L. Sawyer
Supplementary Figure 1. BRCA1 mutations lead to impaired MMC induced DNA damage signaling.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0532760bd962cbf7fc57649914de88e2
https://doi.org/10.1158/2159-8290.22530600.v1
https://doi.org/10.1158/2159-8290.22530600.v1
Autor:
Roger A. Greenberg, Jukka S. Moilanen, Lisa A. Moreau, Kym M. Boycott, A. Micheil Innes, David A. Dyment, Jacek Majewski, Martin Kircher, Jeremy Schwartzentruber, Marketta Kähkönen, Lei Tian, Sarah L. Sawyer
Supplementary Figure 3. BRCA1 mutations result in compromised DNA damage repair.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f20d1c057843a50a7b64621f017be9
https://doi.org/10.1158/2159-8290.22530594.v1
https://doi.org/10.1158/2159-8290.22530594.v1
Autor:
Alan D. D'Andrea, Sara Frias, Sampsa Hautaniemi, Peter K. Sorger, Peter J. Park, Lisa A. Moreau, Connor S. Clairmont, Jia Zhou, Jean-Bernard Lazaro, Fernando Pérez-Villatoro, Caitlin E. Mills, Sandra Ramos, Julieta Domínguez, Huy Nguyen, Doga C. Gulhan, Jaana Oikkonen, Alfredo Rodríguez, Anniina Färkkilä
Supplementary Table 1 showing reagents and antibodies used in the study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87061b7bd6e456e02a9cc0edfef3f0f2
https://doi.org/10.1158/0008-5472.22427539.v1
https://doi.org/10.1158/0008-5472.22427539.v1
Autor:
Alan D. D'Andrea, Sara Frias, Sampsa Hautaniemi, Peter K. Sorger, Peter J. Park, Lisa A. Moreau, Connor S. Clairmont, Jia Zhou, Jean-Bernard Lazaro, Fernando Pérez-Villatoro, Caitlin E. Mills, Sandra Ramos, Julieta Domínguez, Huy Nguyen, Doga C. Gulhan, Jaana Oikkonen, Alfredo Rodríguez, Anniina Färkkilä
Homologous recombination (HR)-deficient cancers are sensitive to poly-ADP ribose polymerase inhibitors (PARPi), which have shown clinical efficacy in the treatment of high-grade serous cancers (HGSC). However, the majority of patients will relapse, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b3b1c429522be4a8ce378533524cbec
https://doi.org/10.1158/0008-5472.c.6512719.v1
https://doi.org/10.1158/0008-5472.c.6512719.v1
Autor:
Alan D. D'Andrea, Sara Frias, Sampsa Hautaniemi, Peter K. Sorger, Peter J. Park, Lisa A. Moreau, Connor S. Clairmont, Jia Zhou, Jean-Bernard Lazaro, Fernando Pérez-Villatoro, Caitlin E. Mills, Sandra Ramos, Julieta Domínguez, Huy Nguyen, Doga C. Gulhan, Jaana Oikkonen, Alfredo Rodríguez, Anniina Färkkilä
Supplementary Table 2 showing the positive and negative GSEA results for each cell line.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ada5c7689f54b90ab15632389f7b35
https://doi.org/10.1158/0008-5472.22427536
https://doi.org/10.1158/0008-5472.22427536
Autor:
Anniina Färkkilä, Alfredo E. Rodriguez, Doga Gulhan, Jean-Bernard Lazaro, Sandra Ramos, Peter J. Park, Connor Clairmont, Julieta Dominguez, Jaana Oikkonen, Huy V. Nguyen, Lisa A. Moreau, Fernando Pérez-Villatoro, Sara Frías, Caitlin E. Mills, Alan D. D'Andrea, Sampsa Hautaniemi, Peter K. Sorger, Jia Zhou
Publikováno v:
Cancer Research. 81:2774-2787
Homologous recombination (HR)-deficient cancers are sensitive to poly-ADP ribose polymerase inhibitors (PARPi), which have shown clinical efficacy in the treatment of high-grade serous cancers (HGSC). However, the majority of patients will relapse, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b5d356a127bdaa63ad0f357be7545a2
https://doi.org/10.1158/0008-5472.can-20-2912
https://doi.org/10.1158/0008-5472.can-20-2912